EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

EpiVax, Inc., a leading player in the field of computational immunology, has recently announced a significant upgrade to its ISPRI™ platform, which is designed for assessing the immunogenicity risk of biopharmaceuticals. This update introduces various AI-powered functionalities that promise to enhance the precision of immunogenicity predictions, contributing to safer and more effective therapeutic interventions.

Groundbreaking Features in the Updated ISPRI™

The latest version of ISPRI™ includes the enhanced JanusMatrix™ 2.1, an updated immunogenicity scoring system, and a refined antibody-drug antibody (ADA) prediction model known as ADA 2.2. These improvements reflect EpiVax's commitment to harnessing the power of artificial intelligence to advance immunoinformatics.

Enhanced JanusMatrix™ 2.1

One of the cornerstone updates is the JanusMatrix™ 2.1 model, which utilizes AI to refine the prediction of immune tolerance. This model does so by evaluating the cross-conservation of human epitopes while considering both expression and prevalence data. The outcome is a more nuanced understanding of therapeutic epitopes and their respective tolerance profiles, which is crucial for assessing the risk of adverse immunogenic reactions.

New JanusMatrix-Adjusted EpiMatrix Scoring System

Building on the advancements of JanusMatrix 2.1, EpiVax has developed a novel immunogenicity scoring system that harmonizes better with clinical immunogenicity outcomes. This integrative scoring, known as JanusMatrix-Adjusted EpiMatrix (JAX), incorporates tolerance potential directly into the evaluations, leading to a more biologically-informed assessment of immunogenicity risks. By doing so, it allows for a clearer insight into the intrinsic density of effector epitopes across various therapeutic modalities.

Upgraded ADA Prediction Model: ADA 2.2

The ADA prediction model also sees enhancements with the introduction of ADA 2.2. This updated model melds epitope-based metrics with biophysical attributes and mechanism-of-action criteria, establishing a more comprehensive evaluation of the immunogenicity risks associated with antibodies. Furthermore, this model has been specifically trained on a diverse array of clinical monoclonal antibodies, showcasing a stronger correlation between predicted and clinically observed immunogenicity, thus bolstering confidence in immunogenicity risk assessments made using the JAX scoring system.

Implications for Biopharmaceutical Development

The improvements instituted by EpiVax significantly elevate the functionality of their in silico risk assessment tools, enhancing both the specificity and predictive value of immunogenicity evaluations. These advancements are timely, aligning with the FDA's recent initiatives advocating for the adoption of new methodologies (NAM) that are pertinent to human health. The powerful insights provided by ISPRI™ will empower developers to identify immunological risks more effectively, protecting the integrity of their assets and minimizing developmental risks.

EpiVax's efforts not only streamline regulatory preparedness but also facilitate the development of safer and more efficacious therapies, a critical factor in today's rapidly evolving biopharmaceutical landscape.

Conclusion

In conclusion, EpiVax's latest enhancements to ISPRI™ mark a noteworthy advance in the realm of immunogenicity assessments. By integrating advanced AI-driven methods, EpiVax is paving the path for biopharmaceutical developers to navigate the complexities of immunogenicity risk, ultimately fostering a more robust market for safe and effective medications. As EpiVax continues to innovate, its commitment to leveraging science and technology to address challenging healthcare needs remains evident.

For further information, opportunities, and inquiries, press contacts can reach out to Sarah Moniz, Business Development and Marketing Manager at EpiVax.